May 22, 2024
Zambia Cholera Vaccines Market

Zambia Cholera Vaccines Market Is Witnessing High Growth Due To Increasing Disease Outbreaks

Zambia relies heavily on cholera vaccines to fight against the growing threat of cholera outbreaks in the region. Cholera has been a persistent public health challenge in Zambia with recurrent epidemics reported every year primarily during the rainy season extending from October to April. Cholera causes acute diarrhea and leads to dehydration, which if left untreated can cause death within hours.

Zambia Cholera Vaccines Market is estimated to be valued at US$ 1.47 million in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2031.

Cholera vaccines help develop immunity against cholera infection and are vital medical interventions to prevent the spread of the disease. The killed, whole-cell oral vaccines when administered provide moderate protection for 3-6 months against the infection. Leading manufacturers are focusing on introducing next-generation oral cholera vaccines that provide longer lasting protection. The increasing risk of cholera outbreaks and growing awareness about the benefits of vaccination are major factors fueling the demand for cholera vaccines in Zambia.

Key Takeaways

Key players operating in the Zambia Cholera Vaccines are Biovac Inc., Valneva SE., EMERGENT, Astellas Pharma Inc, Sanofi, EUBIOLOGICS CO., LTD,Johnson & Johnson Services Inc., Celldex Therapeutics. They collectively account for over 60% share of Zambia’s cholera vaccine market.

Zambia Cholera Vaccines Market Demand has witnessed rising number of cholera outbreaks in the past decade necessitating increased reliance on cholera vaccines as a preventive measure. Furthermore, the focus of government and healthcare agencies on implementing immunization programs is augmenting the adoption of cholera vaccines in the country.

International organizations and NGOs are partnering with Zambian health authorities to provide mass vaccination campaigns especially during the peak cholera season. This is helping increase geographical coverage of cholera immunization programs in Zambia and promoting global expansion of the market.

Market Key Trends

Introduction of novel vaccines: Manufacturers are investing in R&D to develop next-generation oral cholera vaccines that induce stronger immune responses and have longer durability of protection. For instance, Celldex Therapeutics’ lead vaccine candidate CDX-2401 is a recombinant cholera vaccine designed to provide longer lasting protection compared to currently available vaccines.

Porter’s Analysis

Threat of new entrants: Low barrier to entry with established distribution channels and licensing agreements.

Bargaining power of buyers: Several buyers in public and private healthcare sectors drives prices lower.

Bargaining power of suppliers: Few global manufacturers supply vaccine with differentiated products giving them some control over prices.

Threat of new substitutes: No substitutes currently available for cholera vaccines limiting potential threat in future.

Competitive rivalry: Intense competition among major suppliers to gain market share and long term government supply agreements.

Geographical Regions

The Zambia cholera vaccines market in terms of value is concentrated in Lusaka and Kabwe provinces where majority of the population resides and cholera outbreaks are frequently reported. The high population density and lack of access to clean drinking water in these regions contributes significantly to the vaccine demand.

The Copperbelt province is the fastest growing region for the Zambia cholera vaccines market due to rapid urbanization, industrial activity and migration of workers from other countries. The risk of cholera transmission is higher in crowded living conditions common in mining towns exposing more people. Initiatives to promote immunization programs in at risk communities are helping drive stronger sales growth in Copperbelt compared to other parts of the country.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it